Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
A cell-type-specific role for murine Commd1 in liver inflammation.

Biochimica et biophysica acta

Bartuzi P, Wijshake T, Dekker DC, Fedoseienko A, Kloosterhuis NJ, Youssef SA, Li H, Shiri-Sverdlov R, Kuivenhoven JA, de Bruin A, Burstein E, Hofker MH, van de Sluis B.
PMID: 25072958
Biochim Biophys Acta. 2014 Nov;1842(11):2257-65. doi: 10.1016/j.bbadis.2014.06.035. Epub 2014 Jul 27.

The transcription factor NF-κB plays a critical role in the inflammatory response and it has been implicated in various diseases, including non-alcoholic fatty liver disease (NAFLD). Although transient NF-κB activation may protect tissues from stress, a prolonged NF-κB activation...

Cite
Bartuzi P, Wijshake T, Dekker DC, et al. A cell-type-specific role for murine Commd1 in liver inflammation. Biochim Biophys Acta. 2014;1842(11):2257-65doi: 10.1016/j.bbadis.2014.06.035.
Bartuzi, P., Wijshake, T., Dekker, D. C., Fedoseienko, A., Kloosterhuis, N. J., Youssef, S. A., Li, H., Shiri-Sverdlov, R., Kuivenhoven, J. A., de Bruin, A., Burstein, E., Hofker, M. H., & van de Sluis, B. (2014). A cell-type-specific role for murine Commd1 in liver inflammation. Biochimica et biophysica acta, 1842(11), 2257-65. https://doi.org/10.1016/j.bbadis.2014.06.035
Bartuzi, Paulina, et al. "A cell-type-specific role for murine Commd1 in liver inflammation." Biochimica et biophysica acta vol. 1842,11 (2014): 2257-65. doi: https://doi.org/10.1016/j.bbadis.2014.06.035
Bartuzi P, Wijshake T, Dekker DC, Fedoseienko A, Kloosterhuis NJ, Youssef SA, Li H, Shiri-Sverdlov R, Kuivenhoven JA, de Bruin A, Burstein E, Hofker MH, van de Sluis B. A cell-type-specific role for murine Commd1 in liver inflammation. Biochim Biophys Acta. 2014 Nov;1842(11):2257-65. doi: 10.1016/j.bbadis.2014.06.035. Epub 2014 Jul 27. PMID: 25072958; PMCID: PMC4188638.
Copy Download .nbib Format: NLM
Myosteatosis in NAFLD patients correlates with plasma Cathepsin D.

Biomolecular concepts

Ding L, De Munck TJI, Oligschlaeger Y, Dos Reis IM, Verbeek J, Koek GH, Houben T, Shiri-Sverdlov R.
PMID: 33991468
Biomol Concepts. 2021 May 15;12(1):27-35. doi: 10.1515/bmc-2021-0004.

Previously, we have shown that hepatic lipid accumulation induces the secretion of cathepsin D (CTSD), and that plasma CTSD levels are associated with increased inflammation and disease severity in nonalcoholic fatty liver disease (NAFLD). Although it is clear that...

Cite
Ding L, De Munck TJI, Oligschlaeger Y, et al. Myosteatosis in NAFLD patients correlates with plasma Cathepsin D. Biomol Concepts. 2021;12(1):27-35doi: 10.1515/bmc-2021-0004.
Ding, L., De Munck, T. J. I., Oligschlaeger, Y., Dos Reis, I. M., Verbeek, J., Koek, G. H., Houben, T., & Shiri-Sverdlov, R. (2021). Myosteatosis in NAFLD patients correlates with plasma Cathepsin D. Biomolecular concepts, 12(1), 27-35. https://doi.org/10.1515/bmc-2021-0004
Ding, Lingling, et al. "Myosteatosis in NAFLD patients correlates with plasma Cathepsin D." Biomolecular concepts vol. 12,1 (2021): 27-35. doi: https://doi.org/10.1515/bmc-2021-0004
Ding L, De Munck TJI, Oligschlaeger Y, Dos Reis IM, Verbeek J, Koek GH, Houben T, Shiri-Sverdlov R. Myosteatosis in NAFLD patients correlates with plasma Cathepsin D. Biomol Concepts. 2021 May 15;12(1):27-35. doi: 10.1515/bmc-2021-0004. PMID: 33991468.
Copy Download .nbib Format: NLM
Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment.

Frontiers in immunology

Houben T, Yadati T, de Kruijf R, Gijbels MJJ, Luiken JJFP, van Zandvoort M, Kapsokalyvas D, Lütjohann D, Westerterp M, Plat J, Leake D, Shiri-Sverdlov R.
PMID: 34489968
Front Immunol. 2021 Aug 20;12:716357. doi: 10.3389/fimmu.2021.716357. eCollection 2021.

Lifestyle- and genetically induced disorders related to disturbances in cholesterol metabolism have shown the detrimental impact of excessive cholesterol levels on a plethora of pathological processes such as inflammation. In this context, two-hydroxypropyl-β-cyclodextrin (CD) is increasingly considered as a...

Cite
Houben T, Yadati T, de Kruijf R, et al. Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment. Front Immunol. 2021;12:716357doi: 10.3389/fimmu.2021.716357.
Houben, T., Yadati, T., de Kruijf, R., Gijbels, M. J. J., Luiken, J. J. F. P., van Zandvoort, M., Kapsokalyvas, D., Lütjohann, D., Westerterp, M., Plat, J., Leake, D., & Shiri-Sverdlov, R. (2021). Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment. Frontiers in immunology, 12716357. https://doi.org/10.3389/fimmu.2021.716357
Houben, Tom, et al. "Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment." Frontiers in immunology vol. 12 (2021): 716357. doi: https://doi.org/10.3389/fimmu.2021.716357
Houben T, Yadati T, de Kruijf R, Gijbels MJJ, Luiken JJFP, van Zandvoort M, Kapsokalyvas D, Lütjohann D, Westerterp M, Plat J, Leake D, Shiri-Sverdlov R. Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment. Front Immunol. 2021 Aug 20;12:716357. doi: 10.3389/fimmu.2021.716357. eCollection 2021. PMID: 34489968; PMCID: PMC8417873.
Copy Download .nbib Format: NLM
NAFLD Preclinical Models: More than a Handful, Less of a Concern?.

Biomedicines

Oligschlaeger Y, Shiri-Sverdlov R.
PMID: 32046285
Biomedicines. 2020 Feb 08;8(2). doi: 10.3390/biomedicines8020028.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and/or hepatocellular carcinoma. Due to its increasing prevalence, NAFLD is currently a major public health concern. Although a wide...

Cite
Oligschlaeger Y, Shiri-Sverdlov R. NAFLD Preclinical Models: More than a Handful, Less of a Concern?. Biomedicines. 2020;8(2)doi: 10.3390/biomedicines8020028.
Oligschlaeger, Y., & Shiri-Sverdlov, R. (2020). NAFLD Preclinical Models: More than a Handful, Less of a Concern?. Biomedicines, 8(2), . https://doi.org/10.3390/biomedicines8020028
Oligschlaeger, Yvonne, and Shiri-Sverdlov, Ronit. "NAFLD Preclinical Models: More than a Handful, Less of a Concern?." Biomedicines vol. 8,2 (2020). doi: https://doi.org/10.3390/biomedicines8020028
Oligschlaeger Y, Shiri-Sverdlov R. NAFLD Preclinical Models: More than a Handful, Less of a Concern?. Biomedicines. 2020 Feb 08;8(2). doi: 10.3390/biomedicines8020028. PMID: 32046285; PMCID: PMC7167756.
Copy Download .nbib Format: NLM
Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model.

PloS one

Li J, Chanda D, van Gorp PJ, Jeurissen ML, Houben T, Walenbergh SM, Debets J, Oligschlaeger Y, Gijbels MJ, Neumann D, Shiri-Sverdlov R.
PMID: 27685150
PLoS One. 2016 Sep 29;11(9):e0163843. doi: 10.1371/journal.pone.0163843. eCollection 2016.

Non-alcoholic steatohepatitis (NASH) is a common liver disease characterized by hepatic lipid accumulation (steatosis) and inflammation. Currently, therapeutic options are poor and the long-term burden to society is constantly increasing. Previously, macrophage stimulating protein (MSP)-a serum protein mainly secreted...

Cite
Li J, Chanda D, van Gorp PJ, et al. Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS One. 2016;11(9):e0163843doi: 10.1371/journal.pone.0163843.
Li, J., Chanda, D., van Gorp, P. J., Jeurissen, M. L., Houben, T., Walenbergh, S. M., Debets, J., Oligschlaeger, Y., Gijbels, M. J., Neumann, D., & Shiri-Sverdlov, R. (2016). Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PloS one, 11(9), e0163843. https://doi.org/10.1371/journal.pone.0163843
Li, Jieyi, et al. "Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model." PloS one vol. 11,9 (2016): e0163843. doi: https://doi.org/10.1371/journal.pone.0163843
Li J, Chanda D, van Gorp PJ, Jeurissen ML, Houben T, Walenbergh SM, Debets J, Oligschlaeger Y, Gijbels MJ, Neumann D, Shiri-Sverdlov R. Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS One. 2016 Sep 29;11(9):e0163843. doi: 10.1371/journal.pone.0163843. eCollection 2016. PMID: 27685150; PMCID: PMC5042385.
Copy Download .nbib Format: NLM
Antenatal exposure to chorioamnionitis affects lipid metabolism in 7-week-old sheep.

Journal of developmental origins of health and disease

Vlassaks E, Gavilanes AW, Bieghs V, Reinartz A, Gassler N, Van Gorp PJ, Gijbels MJ, Bekers O, Zimmermann LJ, Pillow JJ, Polglase GR, Nitsos I, Newnham JP, Kallapur SG, Jobe AH, Shiri-Sverdlov R, Kramer BW.
PMID: 25101920
J Dev Orig Health Dis. 2012 Apr;3(2):103-10. doi: 10.1017/S2040174412000049.

Antenatal exposure of the fetus to inflammation may alter postnatal organ development. In our previous work, we demonstrated that the fetal liver is involved in the systemic inflammation associated with chorioamnionitis, leading to metabolic changes. On the basis of...

Cite
Vlassaks E, Gavilanes AW, Bieghs V, et al. Antenatal exposure to chorioamnionitis affects lipid metabolism in 7-week-old sheep. J Dev Orig Health Dis. 2012;3(2):103-10doi: 10.1017/S2040174412000049.
Vlassaks, E., Gavilanes, A. W., Bieghs, V., Reinartz, A., Gassler, N., Van Gorp, P. J., Gijbels, M. J., Bekers, O., Zimmermann, L. J., Pillow, J. J., Polglase, G. R., Nitsos, I., Newnham, J. P., Kallapur, S. G., Jobe, A. H., Shiri-Sverdlov, R., & Kramer, B. W. (2012). Antenatal exposure to chorioamnionitis affects lipid metabolism in 7-week-old sheep. Journal of developmental origins of health and disease, 3(2), 103-10. https://doi.org/10.1017/S2040174412000049
Vlassaks, E, et al. "Antenatal exposure to chorioamnionitis affects lipid metabolism in 7-week-old sheep." Journal of developmental origins of health and disease vol. 3,2 (2012): 103-10. doi: https://doi.org/10.1017/S2040174412000049
Vlassaks E, Gavilanes AW, Bieghs V, Reinartz A, Gassler N, Van Gorp PJ, Gijbels MJ, Bekers O, Zimmermann LJ, Pillow JJ, Polglase GR, Nitsos I, Newnham JP, Kallapur SG, Jobe AH, Shiri-Sverdlov R, Kramer BW. Antenatal exposure to chorioamnionitis affects lipid metabolism in 7-week-old sheep. J Dev Orig Health Dis. 2012 Apr;3(2):103-10. doi: 10.1017/S2040174412000049. PMID: 25101920.
Copy Download .nbib Format: NLM
Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice.

Journal of the American Heart Association

Ahmad F, Mitchell RD, Houben T, Palo A, Yadati T, Parnell AJ, Patel K, Shiri-Sverdlov R, Leake DS.
PMID: 34493066
J Am Heart Assoc. 2021 Sep 21;10(18):e017524. doi: 10.1161/JAHA.120.017524. Epub 2021 Sep 08.

Background We have shown previously that low-density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL...

Cite
Ahmad F, Mitchell RD, Houben T, et al. Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice. J Am Heart Assoc. 2021;10(18):e017524doi: 10.1161/JAHA.120.017524.
Ahmad, F., Mitchell, R. D., Houben, T., Palo, A., Yadati, T., Parnell, A. J., Patel, K., Shiri-Sverdlov, R., & Leake, D. S. (2021). Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice. Journal of the American Heart Association, 10(18), e017524. https://doi.org/10.1161/JAHA.120.017524
Ahmad, Feroz, et al. "Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice." Journal of the American Heart Association vol. 10,18 (2021): e017524. doi: https://doi.org/10.1161/JAHA.120.017524
Ahmad F, Mitchell RD, Houben T, Palo A, Yadati T, Parnell AJ, Patel K, Shiri-Sverdlov R, Leake DS. Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice. J Am Heart Assoc. 2021 Sep 21;10(18):e017524. doi: 10.1161/JAHA.120.017524. Epub 2021 Sep 08. PMID: 34493066; PMCID: PMC8649511.
Copy Download .nbib Format: NLM
NASH and Systemic Complications: From Basic to Clinical Research.

Biomedicines

Baumgartner S, Shiri-Sverdlov R.
PMID: 34944726
Biomedicines. 2021 Dec 14;9(12). doi: 10.3390/biomedicines9121913.

Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH) [...].

Cite
Baumgartner S, Shiri-Sverdlov R. NASH and Systemic Complications: From Basic to Clinical Research. Biomedicines. 2021;9(12)doi: 10.3390/biomedicines9121913.
Baumgartner, S., & Shiri-Sverdlov, R. (2021). NASH and Systemic Complications: From Basic to Clinical Research. Biomedicines, 9(12), . https://doi.org/10.3390/biomedicines9121913
Baumgartner, Sabine, and Shiri-Sverdlov, Ronit. "NASH and Systemic Complications: From Basic to Clinical Research." Biomedicines vol. 9,12 (2021). doi: https://doi.org/10.3390/biomedicines9121913
Baumgartner S, Shiri-Sverdlov R. NASH and Systemic Complications: From Basic to Clinical Research. Biomedicines. 2021 Dec 14;9(12). doi: 10.3390/biomedicines9121913. PMID: 34944726.
Copy Download .nbib Format: NLM
Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick Type C1 disease.

Journal of lipid research

Groenen AG, La Rose AM, Li M, Bazioti V, Svendsen AF, Kloosterhuis NJ, Ausema A, Pranger A, Heiner-Fokkema MR, Niezen-Koning KE, Houben T, Shiri-Sverdlov R, Westerterp M.
PMID: 35007562
J Lipid Res. 2022 Jan 07;100167. doi: 10.1016/j.jlr.2021.100167. Epub 2022 Jan 07.

Niemann-Pick Type C1 (NPC1) disease is a progressive lysosomal storage disorder caused by mutations of the NPC1 gene. While neurodegeneration is the most severe symptom, a large proportion of NPC1 patients also present with splenomegaly, which has been attributed...

Cite
Groenen AG, La Rose AM, Li M, et al. Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick Type C1 disease. J Lipid Res. 2022;100167doi: 10.1016/j.jlr.2021.100167.
Groenen, A. G., La Rose, A. M., Li, M., Bazioti, V., Svendsen, A. F., Kloosterhuis, N. J., Ausema, A., Pranger, A., Heiner-Fokkema, M. R., Niezen-Koning, K. E., Houben, T., Shiri-Sverdlov, R., & Westerterp, M. (2022). Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick Type C1 disease. Journal of lipid research, 100167. https://doi.org/10.1016/j.jlr.2021.100167
Groenen, Anouk G, et al. "Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick Type C1 disease." Journal of lipid research vol. (2022): 100167. doi: https://doi.org/10.1016/j.jlr.2021.100167
Groenen AG, La Rose AM, Li M, Bazioti V, Svendsen AF, Kloosterhuis NJ, Ausema A, Pranger A, Heiner-Fokkema MR, Niezen-Koning KE, Houben T, Shiri-Sverdlov R, Westerterp M. Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick Type C1 disease. J Lipid Res. 2022 Jan 07;100167. doi: 10.1016/j.jlr.2021.100167. Epub 2022 Jan 07. PMID: 35007562.
Copy Download .nbib Format: NLM
Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity.

Nutrition & diabetes

Wolfs MG, Gruben N, Rensen SS, Verdam FJ, Greve JW, Driessen A, Wijmenga C, Buurman WA, Franke L, Scheja L, Koonen DP, Shiri-Sverdlov R, van Haeften TW, Hofker MH, Fu J.
PMID: 25664838
Nutr Diabetes. 2015 Feb 09;5:e146. doi: 10.1038/nutd.2014.43.

OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) is an obesity-associated disease, and in obesity adipokines are believed to be involved in the development of NAFLD. However, it is still not clear whether adipokines in the liver and/or adipose tissues can...

Cite
Wolfs MG, Gruben N, Rensen SS, et al. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutr Diabetes. 2015;5:e146doi: 10.1038/nutd.2014.43.
Wolfs, M. G., Gruben, N., Rensen, S. S., Verdam, F. J., Greve, J. W., Driessen, A., Wijmenga, C., Buurman, W. A., Franke, L., Scheja, L., Koonen, D. P., Shiri-Sverdlov, R., van Haeften, T. W., Hofker, M. H., & Fu, J. (2015). Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutrition & diabetes, 5e146. https://doi.org/10.1038/nutd.2014.43
Wolfs, M G M, et al. "Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity." Nutrition & diabetes vol. 5 (2015): e146. doi: https://doi.org/10.1038/nutd.2014.43
Wolfs MG, Gruben N, Rensen SS, Verdam FJ, Greve JW, Driessen A, Wijmenga C, Buurman WA, Franke L, Scheja L, Koonen DP, Shiri-Sverdlov R, van Haeften TW, Hofker MH, Fu J. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity. Nutr Diabetes. 2015 Feb 09;5:e146. doi: 10.1038/nutd.2014.43. PMID: 25664838; PMCID: PMC4338415.
Copy Download .nbib Format: NLM
Nonalcoholic Fatty Liver Disease.

Handbook of experimental pharmacology

Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T.
PMID: 32185502
Handb Exp Pharmacol. 2020 Mar 18; doi: 10.1007/164_2020_352. Epub 2020 Mar 18.

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD...

Cite
Ding L, Oligschlaeger Y, Shiri-Sverdlov R, et al. Nonalcoholic Fatty Liver Disease. Handb Exp Pharmacol. 2020;doi: 10.1007/164_2020_352.
Ding, L., Oligschlaeger, Y., Shiri-Sverdlov, R., & Houben, T. (2020). Nonalcoholic Fatty Liver Disease. Handbook of experimental pharmacology, . https://doi.org/10.1007/164_2020_352
Ding, Lingling, et al. "Nonalcoholic Fatty Liver Disease." Handbook of experimental pharmacology vol. (2020). doi: https://doi.org/10.1007/164_2020_352
Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Nonalcoholic Fatty Liver Disease. Handb Exp Pharmacol. 2020 Mar 18; doi: 10.1007/164_2020_352. Epub 2020 Mar 18. PMID: 32185502.
Copy Download .nbib Format: NLM
Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice.

Journal of the American Heart Association

Ahmad F, Mitchell RD, Houben T, Palo A, Yadati T, Parnell AJ, Patel K, Shiri-Sverdlov R, Leake DS.
PMID: 34493066
J Am Heart Assoc. 2021 Sep 21;10(18):e017524. doi: 10.1161/JAHA.120.017524. Epub 2021 Sep 08.

Background We have shown previously that low-density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL...

Cite
Ahmad F, Mitchell RD, Houben T, et al. Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice. J Am Heart Assoc. 2021;10(18):e017524doi: 10.1161/JAHA.120.017524.
Ahmad, F., Mitchell, R. D., Houben, T., Palo, A., Yadati, T., Parnell, A. J., Patel, K., Shiri-Sverdlov, R., & Leake, D. S. (2021). Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice. Journal of the American Heart Association, 10(18), e017524. https://doi.org/10.1161/JAHA.120.017524
Ahmad, Feroz, et al. "Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice." Journal of the American Heart Association vol. 10,18 (2021): e017524. doi: https://doi.org/10.1161/JAHA.120.017524
Ahmad F, Mitchell RD, Houben T, Palo A, Yadati T, Parnell AJ, Patel K, Shiri-Sverdlov R, Leake DS. Cysteamine Decreases Low-Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low-Density Lipoprotein Receptor-Deficient Mice. J Am Heart Assoc. 2021 Sep 21;10(18):e017524. doi: 10.1161/JAHA.120.017524. Epub 2021 Sep 08. PMID: 34493066.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries